^
Association details:
| Biomarker: | ALK G1269A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial
Published date:
05/15/2020
Excerpt:
Multivariable Cox regression revealed that high level of ctDNA amount and TP53 mutations at BL was significantly associated with poor PFS independently... We observed G1269A, G1202R and E1210K as the major resistant mutations to ensartinib.
DOI:
10.1158/1538-7445.AM2020-2997
Source:
Title:
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Excerpt:
CONTRADICTING EVIDENCE: Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy...Tumours with the secondary resistance mutations F1174L/V (objective response in five [71%] of seven patients with this mutation), G1269A (four [67%] of six), C1156Y (five [71%] of seven), and T1151 (two [67%] of three) were especially sensitive to ensartinib.
DOI:
10.1016/S2213-2600(19)30252-8
Trial ID:
